G.I. Research

Advanced Gastroenterology Associates, LLC, conducts research in selected areas of concern to our patients. Our team participates in research for 2 reasons:

  1. To stay ahead of the latest G.I. treatments by participating in the development and delivery of care. We estimate that we can be 5 years ahead of current methods.
  2. Provide a way to help less fortunate patients who may not be able to afford state of the art G.I. medical treatments.

We conduct our research studies at our Palm Harbor facility. Volunteering to be in a research trial will assist in the development of new medical therapies that may offer better treatments and even cures for life threatening and chronic diseases. Our research trials are regulated by the federal governement and also reviewed by independent ethics committees.

To be considered as a participant into a research study, a signed Informed Consent must be obtained prior to any study related procedures being completed. An Informed Consent will help a study participant understand the purpose, procedures, potential risks and benefits of their involvement, along with alternative treatment if applicable. Participating in a research study is voluntary.

Key points about our research:

  • Insurance is not necessary.
  • Study volunteers may be compensated for time and travel.
  • Study availability changes frequently so please contact our research office for updated status about enrolling trials.
  • Trials open and close at a rapid pace.
  • We will continue to update our research page to keep our patients up to date on the newest research trials.
Joanne Root, CCRC

Certified Clinical Research Coordinator


34041 US Highway 19 North, Suite A
Palm Harbor, FL 34685
Direct Phone ~ 727-216-0768
Fax ~ 727-786-7521

Email ~ research@advancedgastro.com

Like our Facebook research page


Please contact us in our Palm Harbor office or complete the Research Contact Form.

Note: Be sure to download and complete the New Patient Forms before your visit.


BIO-SPECIMEN STUDIES - DONATE YOUR SPECIMEN FOR RESEARCH
If you are a current or new patient you may qualify for one of the following:

One time Blood Specimen study for those diagnosed with Non-Viral Liver Disease

Subjects must not have been diagnosed with Viral Hepatitis (A, B, C, D, E) or HIV

  • Alcoholic Hepatitis
  • Autoimmune Hepatitis
  • Cholangiocarcinoma
  • Cirrhosis
  • Granulomatous Hepatitis
  • Hepatocellular Carcinoma
  • NAFLD
  • NASH
  • Obstructive Jaundice
  • Wilson's Disease

Observational 5-yr registry for those with Ulcerative Colitis or Crohn's Disease
  • Must be under current treatment and being followed as part of Standard of Care with one of our physicians

One time Blood Specimen study for those diagnosed with Cirrhosis
  • Viral and non-viral permitted
  • Imaging or Liver Biopsy Documentation of diagnosis must be present
  • No Cancer within 5 years with exception of basal cell squamous cell carcinomas of the skin

GASTROESOPHAGEAL REFLUX STUDY

REFLUX Treatment for those qualifying and are having breakthrough symptoms on current PPI
Have you been diagnosed with GERD and continue to have persistent symptoms, such as heartburn and regurgitation, while taking your once-daily, standard-dose of PPI's ?

You may qualify to be part of this clinical trial if you are a:

  • Patient between 18 and 65 years of age at the Screening Visit; females must not be pregnant or must not be breastfeeding;
  • Patient with a confirmed diagnosis of gastroesophageal reflux disease, must be currently taking a proton pumpinhibitor (PPI), and must be experiencing GERD symptoms.

This study is to assess the effect of an investigational medication, as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease (GERD).

Before any study-related tests and procedures are performed, you will be asked to read and sign an Informed Consent.

If you decide to participate in this study, you will be asked to receive study drug orally two (2) times daily for 8 weeks and complete five (5) office visits; total participation is expected to last up to 126 days, including the Screening Period.

Qualified study pardcipants will receive the following:

  • Study-related health assessments such as physicals, lab work, ECG's, Upper Endoscopy (EGD) and Bravo Procedure
  • Reimbursement for your time and travel

NASH-Nonalchoholic Steatohepatitis (Fatty Liver)
NASH Treatment for those qualifying

Before any study-related tests and procedures are performed, you will be asked to read and sign an Informed Consent.

  • Male and female subjects of any ethnic origin between the ages of 18 and 75 years
  • Histologic evidence on a historical liver biopsy within 24 months of Screening consistent with NASH with fibrosis (no cirrhosis), and elevated ALT at Screening AND Screening MRI PDFF with >8 % steatosis OR
  • Phenotypic diagnosis of NASH based on elevated ALT and diagnosis of T2DM or pre-diabetes AND Screening MRI PDFF with >8 % steatosis
  • Body mass index (BMI} >25 kg/m2; for Asian-Americans, BMI >23 kg/m2
  • Entry into main trial includes MRE and MRI for final diagnosis

Qualified study pardcipants will receive the following:

  • Study-related health assessments such as physicals, lab work, ECG's, off site MRE/MRI
  • Reimbursement for your time and travel

© Advanced Gastroenterology Associates, LLC. All Rights Reserved -  

Internet Marketing Solutions by: BH Enterprises of East Lake, Inc.